- Home
- BIIB vs SBAC Comparison
BIIB vs SBAC Comparison
Compare BIIB & SBAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- SBAC
- Stock Information
- Founded
- BIIB 1978
- SBAC 1989
- Country
- BIIB United States
- SBAC United States
- Employees
- BIIB N/A
- SBAC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- SBAC Real Estate Investment Trusts
- Sector
- BIIB Health Care
- SBAC Real Estate
- Exchange
- BIIB Nasdaq
- SBAC Nasdaq
- Market Cap
- BIIB 25.1B
- SBAC 24.0B
- IPO Year
- BIIB 1991
- SBAC 1999
- Fundamental
- Price
- BIIB $150.03
- SBAC $214.28
- Analyst Decision
- BIIB Buy
- SBAC Buy
- Analyst Count
- BIIB 27
- SBAC 14
- Target Price
- BIIB $252.20
- SBAC $257.07
- AVG Volume (30 Days)
- BIIB 1.4M
- SBAC 715.9K
- Earning Date
- BIIB 02-11-2025
- SBAC 10-28-2024
- Dividend Yield
- BIIB N/A
- SBAC 1.83%
- EPS Growth
- BIIB 10.05
- SBAC 39.29
- EPS
- BIIB 11.06
- SBAC 6.34
- Revenue
- BIIB $9,607,500,000.00
- SBAC $2,660,958,000.00
- Revenue This Year
- BIIB N/A
- SBAC N/A
- Revenue Next Year
- BIIB N/A
- SBAC $2.94
- P/E Ratio
- BIIB $13.56
- SBAC $33.76
- Revenue Growth
- BIIB N/A
- SBAC N/A
- 52 Week Low
- BIIB $149.94
- SBAC $183.64
- 52 Week High
- BIIB $268.30
- SBAC $256.68
- Technical
- Relative Strength Index (RSI)
- BIIB 25.52
- SBAC 34.60
- Support Level
- BIIB $153.69
- SBAC $214.51
- Resistance Level
- BIIB $158.20
- SBAC $225.06
- Average True Range (ATR)
- BIIB 3.58
- SBAC 4.02
- MACD
- BIIB 0.16
- SBAC -0.43
- Stochastic Oscillator
- BIIB 0.62
- SBAC 7.26
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About SBAC SBA Communications Corporation
SBA Communications owns and operates almost 40,000 cell towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. It owns more than 17,000 towers in the US, which accounted for about 70% of the company's total revenue in 2023. Internationally, SBA's greatest presence is in Brazil, where it operates roughly 10,000 towers. SBA operates as a real estate investment trust.